-
News and Events
- News
- Events
- This month on Synapse
- COVID-19 and life sciences M&A
- Competition law and coronavirus: what’s the connection?
- National perspectives on the CJEU Bayer decision
- Taking security over IP: counting the cost
- The 2020s: Boris Johnson's decade to prove his life sciences plan
- SPC manufacturing waiver (Part 1)
- Arbitration: considerations for life science companies
- IP, divestments, fragmentation and the future: M&A in life sciences
- Life Sciences Disputes webinar series
- The Treatment
- European patent law
- Previous articles
- Patent pools - an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
- Privacy regulator guidance for life sciences and healthcare in light of COVID-19
- A Czech perspective on COVID-19 and healthcare law
- COVID-19 and public compulsory licensing of drugs in Europe
- NHS can procure drugs for use outside of their approved indications if it's cheaper, court says
- Patents diary: April 2020
- Personal protective equipment COVID-19 export restrictions
- The Bolar and related exemptions in Europe: What activity do they cover?
- Right of access to documents in marketing authorisation applications confirmed
- Lower maximum prices of medicines as of April 2020
- Legal uncertainty over EU market access of Swiss medical devices
- Patents diary: March 2020
- Medical devices and managing product liability risks
- Clash of IP and competition to pharma's detriment? The CJEU's decision in the GSK case
- To Neurim or not to Neurim, that is the question
- Changes in the industrial property law of Poland
- Pricing: highlights of the J.P. Morgan Healthcare Conference
- Patents diary: February 2020
- Life sciences products after Brexit: the transition period
- Patent ownership in Europe
- Coming this year: A User's Guide to Intellectual Property in the Life Sciences
- "An ius comune of European Patent Law"
- No automatic compensation for a wrongful PI, rules the CJEU
- SPC manufacturing waiver (Part 2)
- Previous articles
- Funding life sciences companies
- Duties and liabilities of company directors
- Confidentiality and related protection
- Supplementary protection certificates
- Medical devices
- Biologicals and biosimilars
- Protecting & enforcing IP
- Entering into commercial agreements
- Regulatory compliance
- This month on Synapse
- COVID-19 and life sciences M&A
- Competition law and coronavirus: what’s the connection?
- National perspectives on the CJEU Bayer decision
- Taking security over IP: counting the cost
- The 2020s: Boris Johnson's decade to prove his life sciences plan
- SPC manufacturing waiver (Part 1)
- Arbitration: considerations for life science companies
- IP, divestments, fragmentation and the future: M&A in life sciences
- Life Sciences Disputes webinar series
- The Treatment
- European patent law
- Previous articles
< Back
Renewing your lease: know your rights and don't get caught out!
Edward Cooper and Jill Carey discuss how businesses can avoid certain pitfalls when renewing a commercial lease.
More 
The Great Escape: How to terminate your lease, and what to do if you can't
Jill Carey summarise issues to be considered by a company when planning an exit strategy. More
Real Estate
In this toolkit our real estate experts provide information for life sciences companies on legal issues and developments concerning their commercial premises.